SQZ Biotechnologies (SQZ) Financials

Data note: The supplied statements identify the company as SEACOR Marine Holdings Inc. (SMHI), not SQZ Biotechnologies (OTCMKTS: SQZB). The analysis below reflects the SMHI data provided and should not be attributed to SQZB without corrected financial statements.

Based on the supplied quarterly statements, SMHI’s results show a meaningful second-quarter 2026 improvement in earnings, but the business still generated negative operating cash flow and remains highly dependent on asset sales and debt management.

• Q2 2026 returned to profitability: Revenue increased to $54.6 million from $44.3 million in Q1 2026, while net income improved from a $15.8 million loss to $3.3 million of profit. Diluted EPS improved to $0.12 from negative $0.61.
• Operating performance improved sequentially: Operating income rose to $16.0 million in Q2 2026 from an operating loss of $6.4 million in Q1. However, the reported impairment presentation makes comparisons more difficult because impairment values are shown as negative operating expenses.
• Cash increased during Q2: Cash and equivalents rose to $55.4 million from $38.7 million at the end of Q1, while total cash and restricted cash increased to approximately $93.0 million.
• Debt declined modestly: Short- and long-term debt totaled approximately $320.2 million at June 30, 2026, down from $327.4 million in Q1 and $341.0 million in Q2 2025. The company also made a $7.5 million debt repayment during Q2.
• Liquidity remained adequate on the reported balance sheet: Current assets of $168.3 million exceeded current liabilities of $70.8 million, producing a current ratio of approximately 2.4.
• Revenue remains below prior-year levels: Q2 2026 revenue was 10% lower than the $60.8 million reported in Q2 2025 and substantially below the $69.8 million recorded in Q2 2024.
• Asset sales drove investing cash flow: Q2 investing activities generated $38.3 million, largely because the company sold property, plant and equipment for $44.7 million. This improved cash balances but may not represent recurring operating strength.
• Operating cash flow remained negative: The company used $13.2 million of cash in operating activities during Q2 2026, following a $15.1 million outflow in Q1. Operating cash flow has generally been weak across the supplied periods, despite occasional quarterly profits.
• Interest costs remain a major burden: Q2 interest expense was $8.2 million, and cash interest paid was $13.2 million. High financing costs continue to reduce the benefit of improved operating earnings.
• Long-term financial risk remains elevated: Total liabilities were $381.0 million compared with equity of $252.3 million, while retained earnings remained negative at $221.0 million. Continued operating cash burn could increase reliance on asset sales, refinancing or additional capital.

Overall, the latest quarter showed a favorable sequential rebound in revenue, operating income and net income. Nevertheless, investors should distinguish this improvement from sustainable cash generation: operating cash flow remained negative, and the quarterly cash increase was primarily supported by selling assets rather than by the core business.

The data also includes several restated and calculated historical statements, and some reported line items—particularly impairment charges and investing cash flows—require review against the company’s filings. Investors should verify the ticker and company identity before using these figures for an investment decision.